Combined antipsychotic treatment involving clozapine and aripiprazole

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 6, 2008, Pages 1386-1392

  Englisch, Susanne ^a   Zink, Mathias ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Aripiprazole; Augmentation; Clozapine; Combination; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; ELCRIT; FLUOXETINE; NEUROLEPTIC AGENT; PROLACTIN; RISPERIDONE; SERTRALINE; VENLAFAXINE; ZIPRASIDONE;

ADD ON THERAPY; AGITATION; ANXIETY; BIPOLAR DEPRESSION; DATA ANALYSIS; DATA BASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; HEADACHE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MONOTHERAPY; NAUSEA; NEUROBIOLOGY; NEUROLEPTIC MALIGNANT SYNDROME; OBSESSIVE COMPULSIVE DISORDER; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT INTERVAL; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; HUMANS; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WEIGHT LOSS;

EID: 47749112800     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.02.010     Document Type: Review

References (62)

1. Abu-Tair F., Kopitz J., and Bergemann N. Clozapine augmented with aripirpazole in 5 patients with schizophrenia. J Clin Psychopharmacol 26 6 (2006) 669-671
2. Anil Yagcioglu A.E., Kivircik Akdede B.B., Turgut T.I., Tumuklu M., Yazici M.K., Alptekin K., et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 66 1 (2005) 63-72
3. Ashton A.K. Aripiprazole augmentation of clozapine in refractory schizophrenia. Psychiatry 2 (2005) 18-19
4. Bennett M.R. Monoaminergic synapses and schizophrenia: 45 years of neuroleptics. J Psychopharmacol 12 3 (1998) 289-304
5. Bowles T.M., and Levin G.M. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother 37 5 (2003) 687-694
6. Buchanan R.W. Clozapine: efficacy and safety. Schizophr Bull 21 4 (1995) 579-591
7. Buckley P., Miller A., Olsen J., Garver D., Miller D.D., and Csernansky J. When symptoms persist: clozapine augmentation strategies. Schizophr Bull 27 4 (2001) 615-628
8. Chong S.A., and Remington G. Clozapine augmentation: safety and efficacy. Schizophr Bull 26 2 (2000) 421-440
9. Clarke L.A., Lindenmayer J.P., and Kaushik S. Clozapine augmentation with aripiprazole for negative symptoms. J Clin Psychiatry 67 4 (2006) 675-676
10. Cohen S.T., Rulf D., and Pies R. Extrapyramidal side effects associated with aripiprazole coprescription in 2 patients. J Clin Psychiatry 66 1 (2005) 135-136
11. Connor K.M., Payne V.M., Gadde K.M., Zhang W., Davidson J.R., Connor K.M., et al. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66 1 (2005) 49-51
12. DeQuardo J.R. Increased efficacy with addition of clozapine to aripiprazole: alternative explanations. J Clin Psychiatry 66 3 (2005) 396
13. Duggal H.S. Aripirazole-olanzapine combination for treatment of schizophrenia. Can J Psychiatry 49 2 (2004) 151
14. Duggal H.S., and Kithas J. Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine. Am J Psychiatry 162 2 (2005) 397-398
15. El-Sayeh H.G., and Morganti C. Aripiprazole for schizophrenia [update of Cochrane Database Syst Rev. 2004;(2):CD004578; PMID: 15106256]. Cochrane Database Syst Rev 2 (2006) CD004578
16. El-Sayeh H.G., Morganti C., and Adams C.E. Aripiprazole for schizophrenia. Br J Psychiatry 189 (2006) 102-108
17. Emsley R., and Oosthuizen P. Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 7 2 (2004) 219-238
18. Freudenreich O., Henderson D.C., Walsh J.P., Culhane M.A., and Goff D.C. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 92 (2007) 90-94
19. Hellewell J.S. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry 60 Suppl 23 (1999) 14-19
20. Henderson D.C., Kunkel L., Nguyen D.D., Borba C.P., Daley T.B., Louie P.M., et al. An exploratory open label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 113 (2006) 142-147
21. Honer W.G., Thornton A.E., Chen E.Y., Chan R.C., Wong J.O., Bergmann A., et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. NE J Med 354 5 (2006) 472-482
22. Horacek J. Novel antipsychotics and extrapyramidal side effects. Theory and reality. Pharmacopsychiatry 33 Suppl 1 (2000) 34-42
23. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., and Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441 3 (2002) 137-140
24. Josiassen R.C., Joseph A., Kohegyi E., Stokes S., Dadvand M., Paing W.W., et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 162 1 (2005) 130-136
25. Kane J., Honigfeld G., Singer J., and Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45 9 (1988) 789-796
26. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63 9 (2002) 763-771
27. Karunakaran K., Tungaraza T.E., and Harborne G. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?. J Psychopharmacol 21 4 (2007) 453-456
28. Kaye N.S. Ziprasidone augmentation of clozapine in 11 patients. J Clin Psychiatry 64 2 (2003) 215-216
29. Keck Jr. P.E. Long-term management strategies to achieve optimal function in patients with bipolar disorder. J Clin Psychiatry 67 Suppl 9 (2006) 19-24
30. Kontaxakis V.P., Ferentinos P.P., Havaki-Kontaxaki B.J., Paplos K.G., Roukas D.K., and Christodoulou G.N. Case studies of adjunctive agents in clozapine-resistant schizophrenic patients. Clin Neuropharmacol 28 1 (2005) 50-53
31. Kontaxakis V.P., Ferentinos P.P., Havaki-Kontaxaki B.J., and Roukas D.K. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatr 20 5-6 (2005) 409-415
32. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20 6 (1999) 612-627
33. Lim S., Pralea C., Schnitt J., Bowers Jr. M.B., and Cooper C. Possible increased efficacy of low-dose clozapine when combined with aripiprazole. J Clin Psychiatry 65 9 (2004) 1284-1285
34. Lykouras L., Alevizos B., Michalopoulou P., and Rabavilas A. Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Progr Neuro-Psychopharmacol Biol Psychiatry 27 3 (2003) 333-346
35. Matthiasson P., Erlandsson K., Costa D.C., Waddington W., Visvikis D., Collum I., et al. Amisulpride augmentation of clozapine and striatal dopamine d2 receptor binding potential. A 123-I-IBZM study. Schizophr Res 53 Suppl. 3 (2003) 208
36. Meltzer H.Y. An overview of the mechanism of action of clozapine. J Clin Psychiatry 55 Suppl B (1994) 47-52
37. Miller D.D. Review and management of clozapine side effects. J Clin Psychiatry 61 Suppl 8 (2000) 14-17 discussion 18-9
38. Mitsonis C.I., Dimopoulos N.P., Mitropoulos P.A., Kararizou E.G., Katsa A.N., Tsakiris F.E., et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot study. Progr Neuro-Psychopharmacol Biol Psychiatry 31 2 (2006) 373-374
39. Munro J., Matthiasson P., Osborne S., Travis M., Purcell S., Cobb A.M., et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 110 (2004) 292-298
40. Papakostas G.I., Petersen T.J., Kinrys G., Burns A.M., Worthington J.J., Alpert J.E., et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 66 10 (2005) 1326-1330
41. Paton C., Whittington C., and Barnes T.R. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol 27 2 (2007) 198-204
42. Reinstein M.J., Sonnenberg J.G., Mohan S.C., Chasanov M.A., and Jones L.E. Use of quetiapine to manage patients who experienced adverse effects with clozapine. Clin Drug Investig 23 1 (2003) 63-67
43. Rocha F.L., and Hara C. Benefits of combining aripiprazole to clozapine: three case reports. Progr Neuro-Psychopharmacol Biol Psychiatry 30 6 (2006) 1167-1169
44. Sethi K.D. Movement disorders induced by dopamine blocking agents. Sem Neurol 21 1 (2001) 59-68
45. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28 80 (2003) 1400-1411
46. Shiloh R., Zemishlany Z., Aizenberg D., Radwan M., Schwartz B., Dorfman-Etrog P., et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 171 (1997) 569-573
47. Simon J.S., and Nemeroff C.B. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 66 10 (2005) 1216-1220
48. Sobhan T., Sobhan F., Feldman J.M., and Ryan W.G. Medication options for treatment-resistant schizophrenia: implications for global mental health financing. Int J Psychiatry Clin Pract 10 3 (2007) 213-219
49. Stahl S.M., and Grady M.M. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 11 3 (2004) 313-327
50. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64 6 (2003) 663-667
51. Ziegenbein M., and Calliess I.T. Clozapine and ziprasidone: a useful combination in patients with treatment-resistant schizophrenia. J Neuropsychiatry Clin Neurosci 18 2 (2006) 246-247
52. Ziegenbein M., Rosenthal O., Machleidt W., and Garlipp P. Coadministration of clozapine and amisulpride in patients with schizophrenia. Biol Psychiatry 53 (2003) 48S
53. Ziegenbein M., Kropp S., and Kuenzel H.E. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clin Neuropharmacol 28 5 (2005) 220-224
54. Ziegenbein M., Sieberer M., Calliess I.T., and Kropp S. Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia. Austr NZ J Psychiatry 39 9 (2005) 840-841
55. Ziegenbein M., Wittmann G., and Kropp S. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia - a clinical observation. Clin Drug Investig 26 3 (2006) 117-124
56. Zink M. Optimizing the antipsychotic potency of olanzapine by augmentation: a critical review. Psychiatr Praxis 33 (2006) 261-268
57. Zink M., and Dressing H. Augmentation of clozapine with atypical antipsychotic substances. Curr Psychiatry Rev 1 2 (2005) 165-172
58. Zink M., Knopf U., Henn F.A., and Thome J. Combination of clozapine and amisulpride in treatment-resistant schizophrenia - case reports and review of the literature. Pharmacopsychiatry 37 1 (2004) 26-31
59. Zink M., Mase E., and Dressing H. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia. Hum Psychopharmacol 19 4 (2004) 271-273
60. Zink M., Mase E., and Dressing H. Ziprasidone-augmentation of clozapine. Psychiatr Praxis 31 (2004) 259-261
61. Zink M., Knopf U., and Kuwilsky A. Management of clozapine-induced obsessive compulsive symptoms in a man with schizophrenia. Austr NZ J Psychiatry 41 3 (2006) 293-294
62. Zink M, Kuwilsky A, Krumm B, & Dressing H, Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomized controlled clinical trial. J Psychopharmacol in press.